Table 3 Baseline characteristics of patients with TAK taking PPIs with/without surgical and endovascular events
From: Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis
|  | TAK with events (n = 14) | TAK without events (n = 41) | P value |
|---|---|---|---|
Age, years (IQR) | 60 (29–69) | 54 (34–72) | 0.8747 |
Female, n, % | 10, 71.4 | 35, 85.4 | 0.2552 |
Body mass index, kg/m2 (IQR) | 22.7 (21.2–25.2) | 22.4 (19.9–24.5) | 0.4868 |
Duration of disease, years (IQR)a | 12.0 (3.0–48.0) | 11.5 (3.8–18.3) | 0.6727 |
Inflammatory bowel disease, n, % | 3, 21.4 | 4, 9.8 | 0.3537 |
HLA-B52 positivity, n, % | 9, 64.3 | 24, 58.5 | 0.7620 |
CRP, mg/dL, mean ± SD | 0.18 ± 0.34 | 0.24 ± 0.55 | 0.4880 |
ESR, mm/hourb | 9.00 ± 10.08 | 9.79 ± 10.44 | 0.7517 |
Triglyceride, mg/dL, mean ± SD | 139 ± 100 | 104 ± 51 | 0.3440 |
LDL cholesterol, mg/dL, mean ± SD | 108 ± 44 | 106 ± 25 | 0.8945 |
HDL cholesterol, mg/dL, mean ± SD | 67 ± 15 | 64 ± 18 | 0.5435 |
Smoking (current or past) n, % | 3, 21.4 | 10, 24.4 |  > 0.9999 |
Medication | Â | Â | Â |
 Anti-hypertension drug, n, % | 9, 64.3 | 17, 41.5 | 0.2154 |
 Statin, n, % | 10, 71.4 | 17, 41.5 | 0.0683 |
 Metformin, n, % | 0, 0 | 1, 2.4 |  > 0.9999 |
 Proton pump inhibitor, n, % | 14, 100.0 | 41, 100.0 |  > 0.9999 |
 Antiplatelet, n, % | 6, 42.9 | 30, 73.2 | 0.0542 |
 Glucocorticoid, n, % | 13, 92.9 | 30, 73.2 | 0.1562 |
 Mean dose of prednisolone (mg/day), mean ± SD | 7.82 ± 5.32 | 5.60 ± 4.79 | 0.1725 |
 Methotrexate, n, % | 1, 7.1 | 7, 17.1 | 0.6639 |
 Azathioprine, n, % | 3, 21.4 | 4, 9.8 | 0.3537 |
 Cyclosporine, n, % | 1, 7.1 | 0, 0 | 0.2545 |
 Tacrolimus, n, % | 0, 0 | 0, 0 |  > 0.9999 |
 5-aminosalicyclic acid, n, % | 2, 14.3 | 3, 7.3 | 0.5924 |
 Tocilizumab, n, % | 7, 50.0 | 19, 46.3 |  > 0.9999 |
 TNF inhibitor, n, % | 1, 7.1 | 2, 4.9 |  > 0.9999 |
 Antibiotics, n, % | 7, 50.0 | 10, 24.4 | 0.0983 |